Difficult-to-treat rheumatoid arthritis: contributing factors and burden of disease

Treatment of difficult-to-treat (D2T) RA patients is generally based on trial-and-error and can be challenging due to a myriad of contributing factors. We aimed to identify risk factors at RA onset, contributing factors and the burden of disease. Consecutive RA patients were enrolled and categorised...

Full description

Saved in:
Bibliographic Details
Published inRheumatology (Oxford, England) Vol. 60; no. 8; pp. 3778 - 3788
Main Authors Roodenrijs, Nadia M T, van der Goes, Marlies C, Welsing, Paco M J, Tekstra, Janneke, Lafeber, Floris P J G, Jacobs, Johannes W G, van Laar, Jacob M
Format Journal Article
LanguageEnglish
Published England 02.08.2021
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Treatment of difficult-to-treat (D2T) RA patients is generally based on trial-and-error and can be challenging due to a myriad of contributing factors. We aimed to identify risk factors at RA onset, contributing factors and the burden of disease. Consecutive RA patients were enrolled and categorised as D2T, according to the EULAR definition, or not (controls). Factors potentially contributing to D2T RA and burden of disease were assessed. Risk factors at RA onset and factors independently associated with D2T RA were identified by logistic regression. D2T RA subgroups were explored by cluster analysis. Fifty-two RA patients were classified as D2T and 100 as non-D2T.Lower socioeconomic status at RA onset was found as an independent risk factor for developing D2T RA (OR 1.97 (95%CI 1.08-3.61)). Several contributing factors were independently associated with D2T RA, occurring more frequently in D2T than non-D2T patients: limited drug options because of adverse events (94% vs 57%) or comorbidities (69% vs 37%), mismatch in patient's and rheumatologist's wish to intensify treatment (37% vs 6%), concomitant fibromyalgia (38% vs 9%) and poorer coping (worse levels). Burden of disease was significantly higher in D2T RA patients. Three subgroups of D2T RA patients were identified: 1) 'non-adherent dissatisfied patients'; 2) patients with 'pain syndromes and obesity'; 3) patients closest to the concept of 'true refractory RA'. This comprehensive study on D2T RA shows multiple contributing factors, a high burden of disease and the heterogeneity of D2T RA. These findings suggest that these factors should be identified in daily practice in order to tailor therapeutic strategies further to the individual patient.
AbstractList Treatment of difficult-to-treat (D2T) RA patients is generally based on trial-and-error and can be challenging due to a myriad of contributing factors. We aimed to identify risk factors at RA onset, contributing factors and the burden of disease. Consecutive RA patients were enrolled and categorised as D2T, according to the EULAR definition, or not (controls). Factors potentially contributing to D2T RA and burden of disease were assessed. Risk factors at RA onset and factors independently associated with D2T RA were identified by logistic regression. D2T RA subgroups were explored by cluster analysis. Fifty-two RA patients were classified as D2T and 100 as non-D2T.Lower socioeconomic status at RA onset was found as an independent risk factor for developing D2T RA (OR 1.97 (95%CI 1.08-3.61)). Several contributing factors were independently associated with D2T RA, occurring more frequently in D2T than non-D2T patients: limited drug options because of adverse events (94% vs 57%) or comorbidities (69% vs 37%), mismatch in patient's and rheumatologist's wish to intensify treatment (37% vs 6%), concomitant fibromyalgia (38% vs 9%) and poorer coping (worse levels). Burden of disease was significantly higher in D2T RA patients. Three subgroups of D2T RA patients were identified: 1) 'non-adherent dissatisfied patients'; 2) patients with 'pain syndromes and obesity'; 3) patients closest to the concept of 'true refractory RA'. This comprehensive study on D2T RA shows multiple contributing factors, a high burden of disease and the heterogeneity of D2T RA. These findings suggest that these factors should be identified in daily practice in order to tailor therapeutic strategies further to the individual patient.
Treatment of difficult-to-treat (D2T) RA patients is generally based on trial-and-error and can be challenging due to a myriad of contributing factors. We aimed to identify risk factors at RA onset, contributing factors and the burden of disease.OBJECTIVESTreatment of difficult-to-treat (D2T) RA patients is generally based on trial-and-error and can be challenging due to a myriad of contributing factors. We aimed to identify risk factors at RA onset, contributing factors and the burden of disease.Consecutive RA patients were enrolled and categorized as D2T, according to the EULAR definition, or not (controls). Factors potentially contributing to D2T RA and burden of disease were assessed. Risk factors at RA onset and factors independently associated with D2T RA were identified by logistic regression. D2T RA subgroups were explored by cluster analysis.METHODSConsecutive RA patients were enrolled and categorized as D2T, according to the EULAR definition, or not (controls). Factors potentially contributing to D2T RA and burden of disease were assessed. Risk factors at RA onset and factors independently associated with D2T RA were identified by logistic regression. D2T RA subgroups were explored by cluster analysis.Fifty-two RA patients were classified as D2T and 100 as non-D2T. Lower socioeconomic status at RA onset was found as an independent risk factor for developing D2T RA [odds ratio (OR) 1.97 (95%CI 1.08-3.61)]. Several contributing factors were independently associated with D2T RA, occurring more frequently in D2T than in non-D2T patients: limited drug options because of adverse events (94% vs 57%) or comorbidities (69% vs 37%), mismatch in patient's and rheumatologist's wish to intensify treatment (37% vs 6%), concomitant fibromyalgia (38% vs 9%) and poorer coping (worse levels). Burden of disease was significantly higher in D2T RA patients. Three subgroups of D2T RA patients were identified: (i) 'non-adherent dissatisfied patients'; (ii) patients with 'pain syndromes and obesity'; (iii) patients closest to the concept of 'true refractory RA'.RESULTSFifty-two RA patients were classified as D2T and 100 as non-D2T. Lower socioeconomic status at RA onset was found as an independent risk factor for developing D2T RA [odds ratio (OR) 1.97 (95%CI 1.08-3.61)]. Several contributing factors were independently associated with D2T RA, occurring more frequently in D2T than in non-D2T patients: limited drug options because of adverse events (94% vs 57%) or comorbidities (69% vs 37%), mismatch in patient's and rheumatologist's wish to intensify treatment (37% vs 6%), concomitant fibromyalgia (38% vs 9%) and poorer coping (worse levels). Burden of disease was significantly higher in D2T RA patients. Three subgroups of D2T RA patients were identified: (i) 'non-adherent dissatisfied patients'; (ii) patients with 'pain syndromes and obesity'; (iii) patients closest to the concept of 'true refractory RA'.This comprehensive study on D2T RA shows multiple contributing factors, a high burden of disease and the heterogeneity of D2T RA. These findings suggest that these factors should be identified in daily practice in order to tailor therapeutic strategies further to the individual patient.CONCLUSIONSThis comprehensive study on D2T RA shows multiple contributing factors, a high burden of disease and the heterogeneity of D2T RA. These findings suggest that these factors should be identified in daily practice in order to tailor therapeutic strategies further to the individual patient.
Author Jacobs, Johannes W G
van Laar, Jacob M
Roodenrijs, Nadia M T
Welsing, Paco M J
van der Goes, Marlies C
Lafeber, Floris P J G
Tekstra, Janneke
Author_xml – sequence: 1
  givenname: Nadia M T
  orcidid: 0000-0002-4364-3183
  surname: Roodenrijs
  fullname: Roodenrijs, Nadia M T
  organization: Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
– sequence: 2
  givenname: Marlies C
  surname: van der Goes
  fullname: van der Goes, Marlies C
  organization: Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands, Department of Rheumatology, Meander Medical Center, Amersfoort, The Netherlands
– sequence: 3
  givenname: Paco M J
  surname: Welsing
  fullname: Welsing, Paco M J
  organization: Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
– sequence: 4
  givenname: Janneke
  surname: Tekstra
  fullname: Tekstra, Janneke
  organization: Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
– sequence: 5
  givenname: Floris P J G
  surname: Lafeber
  fullname: Lafeber, Floris P J G
  organization: Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
– sequence: 6
  givenname: Johannes W G
  surname: Jacobs
  fullname: Jacobs, Johannes W G
  organization: Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
– sequence: 7
  givenname: Jacob M
  surname: van Laar
  fullname: van Laar, Jacob M
  organization: Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33331946$$D View this record in MEDLINE/PubMed
BookMark eNp9kDtPwzAUhS1URB_wDxDyyBKw4yR2uqHylCoxAHPk2NetIY2L7Qz996TqQ4iBu5w7fOcM3xgNWtcCQpeU3FBSslu_hG4lo2vcYnP7BVKKgpygEc2KNCGMpYPjn2ZDNA7hkxCSUybO0JD1R8usGKG3e2uMVV0Tk-iS6EFGfFi2Gksfl95GG6ZYuTZ6W3fRtgtspIrOByxbjevOa2ixM1jbADLAOTo1sglwsc8J-nh8eJ89J_PXp5fZ3TxRjPCYqJoazcpaC0OUyNKUaGN0LjgVpi4NcG64krXIdZmbvKA6I1IBcAlQME40m6Dr3e7au-8OQqxWNihoGtmC60KVZpyIssxZ2qNXe7SrV6Crtbcr6TfVQUQPZDtAeReCB3NEKKm2vqvfvqu97742_VNTNspot66kbf4v_wAKcY-8
CitedBy_id crossref_primary_10_1016_j_intimp_2023_110860
crossref_primary_10_1016_j_intimp_2024_111795
crossref_primary_10_1016_j_autrev_2024_103694
crossref_primary_10_1186_s41927_023_00329_8
crossref_primary_10_3390_ijms252212019
crossref_primary_10_1016_S2468_1253_23_00154_1
crossref_primary_10_2147_IJWH_S482294
crossref_primary_10_2196_30829
crossref_primary_10_1007_s40266_022_00976_5
crossref_primary_10_1186_s13075_025_03491_1
crossref_primary_10_3389_fmed_2024_1497756
crossref_primary_10_3390_ijerph192315861
crossref_primary_10_1038_s41392_023_01331_9
crossref_primary_10_1038_s41584_024_01083_y
crossref_primary_10_1089_jmxr_2024_0024
crossref_primary_10_4078_jrd_22_0005
crossref_primary_10_47360_1995_4484_2024_535_541
crossref_primary_10_1016_j_arr_2024_102249
crossref_primary_10_1016_S2665_9913_24_00340_0
crossref_primary_10_46497_ArchRheumatol_2024_10567
crossref_primary_10_1007_s40744_023_00590_w
crossref_primary_10_1186_s13075_024_03369_8
crossref_primary_10_1055_a_1554_1662
crossref_primary_10_1097_MD_0000000000032154
crossref_primary_10_1080_03009742_2023_2196781
crossref_primary_10_1093_rheumatology_keac134
crossref_primary_10_1093_rheumatology_keac139
crossref_primary_10_2147_PRBM_S428892
crossref_primary_10_1186_s43166_023_00221_w
crossref_primary_10_1080_03007995_2022_2050108
crossref_primary_10_1136_rmdopen_2020_001511
crossref_primary_10_1155_mi_1995952
crossref_primary_10_3390_jcm14051529
crossref_primary_10_1186_s42358_024_00396_6
crossref_primary_10_37349_emd_2024_00050
crossref_primary_10_3390_jpm12101618
crossref_primary_10_1093_rheumatology_keaf120
crossref_primary_10_1016_j_autrev_2023_103423
crossref_primary_10_1093_rheumatology_keae544
crossref_primary_10_1371_journal_pone_0289760
crossref_primary_10_1016_j_ejim_2024_04_026
crossref_primary_10_1016_j_intimp_2023_110655
crossref_primary_10_12998_wjcc_v11_i11_2474
crossref_primary_10_1136_rmdopen_2021_002058
crossref_primary_10_3389_fimmu_2024_1408501
crossref_primary_10_1007_s10067_024_07282_y
crossref_primary_10_3390_jcm13247594
crossref_primary_10_1093_rheumatology_keae265
crossref_primary_10_1093_rheumatology_keac114
crossref_primary_10_1007_s10067_023_06862_8
crossref_primary_10_1007_s11926_023_01117_6
crossref_primary_10_3389_fmed_2022_991677
crossref_primary_10_1136_rmdopen_2022_002387
crossref_primary_10_37349_emd_2024_00032
crossref_primary_10_1002_acr2_11442
crossref_primary_10_1093_ecco_jcc_jjae145
crossref_primary_10_1093_rheumatology_keac190
crossref_primary_10_1515_ohe_2023_0040
crossref_primary_10_1007_s13555_024_01209_w
crossref_primary_10_1093_rheumatology_keae131
crossref_primary_10_1007_s00296_023_05349_8
crossref_primary_10_1093_rap_rkae019
crossref_primary_10_1016_j_jhazmat_2024_133658
crossref_primary_10_14412_1996_7012_2023_3_82_88
crossref_primary_10_1002_art_42767
crossref_primary_10_1136_rmdopen_2024_004180
crossref_primary_10_1136_rmdopen_2023_003808
crossref_primary_10_14412_1996_7012_2022_5_94_100
crossref_primary_10_1016_j_hsr_2023_100108
crossref_primary_10_1007_s40744_023_00560_2
crossref_primary_10_1186_s13075_024_03390_x
crossref_primary_10_3389_fmed_2022_1049875
crossref_primary_10_1007_s00296_022_05124_1
crossref_primary_10_1080_08916934_2023_2181234
crossref_primary_10_1159_000541488
crossref_primary_10_1007_s10067_024_06888_6
crossref_primary_10_1016_j_yexcr_2022_113441
crossref_primary_10_1186_s13075_022_02892_w
crossref_primary_10_1093_rheumatology_keac584
crossref_primary_10_1007_s11845_021_02858_y
crossref_primary_10_2147_OARRR_S408894
crossref_primary_10_1186_s13075_021_02560_5
crossref_primary_10_1136_rmdopen_2022_002842
crossref_primary_10_1177_1357633X221150724
crossref_primary_10_3899_jrheum_220729
crossref_primary_10_1002_jcla_24231
crossref_primary_10_1016_j_crphar_2024_100178
crossref_primary_10_14412_1996_7012_2022_2_13_20
crossref_primary_10_1186_s13075_024_03432_4
crossref_primary_10_1093_rheumatology_kead261
crossref_primary_10_4103_ijar_ijar_3_22
crossref_primary_10_1080_03009742_2023_2277542
crossref_primary_10_1093_rheumatology_keac563
crossref_primary_10_1039_D4BM01058B
crossref_primary_10_1016_j_phymed_2024_156354
crossref_primary_10_1186_s41927_024_00423_5
crossref_primary_10_1016_j_semarthrit_2024_152572
crossref_primary_10_1038_s41598_024_73471_z
crossref_primary_10_1186_s40824_023_00458_8
crossref_primary_10_1038_s41598_025_87318_8
crossref_primary_10_1136_rmdopen_2023_003382
crossref_primary_10_1007_s13577_023_00873_y
crossref_primary_10_1017_S0033291721004943
crossref_primary_10_1016_j_autrev_2024_103516
Cites_doi 10.1016/S0140-6736(00)04170-2
10.1007/s11926-015-0550-z
10.1136/annrheumdis-2017-212256
10.1007/s10067-019-04579-1
10.1136/annrheumdis-2019-216655
10.1136/ard.62.9.897
10.1177/1759720X20904850
10.3390/ijms151222279
10.1016/j.jpsychores.2005.10.020
10.1016/0168-8510(90)90421-9
10.1038/s41584-019-0217-7
10.1016/j.semarthrit.2012.09.003
10.1136/annrheumdis-2020-eular.872
10.1093/rheumatology/keu334
10.1136/annrheumdis-2020-217344
10.1136/ard.59.10.794
10.1016/j.jbspin.2011.04.008
10.1136/ard.61.7.660
10.1111/1756-185X.13774
10.1016/j.jbspin.2018.08.006
10.1136/annrheumdis-2012-203158
10.1249/01.MSS.0000078924.61453.FB
10.1007/s10067-019-04574-6
10.1136/annrheumdis-2017-212862
10.3899/jrheum.100594
10.1093/rheumatology/keq202
10.1038/nrrheum.2013.4
10.1038/nrrheum.2017.115
10.1007/s10067-019-04900-y
10.1037/0022-006X.69.6.1026
10.1136/ard.2010.138461
10.1136/annrheumdis-2018-214147
10.1136/annrheumdis-2018-213687
10.1002/art.24430
10.1136/annrheumdis-2018-214153
10.1093/rheumatology/ken057
10.1093/rheumatology/kez222
10.1093/rheumatology/keh334
10.1111/j.1600-0447.1983.tb09716.x
10.1136/annrheumdis-2019-216151
10.1097/MD.0000000000006983
10.1155/2015/217047
10.1002/art.11200
10.1136/annrheumdis-2018-213378
10.1186/ar4092
10.1002/acr.20620
10.1016/j.semarthrit.2008.01.011
10.1016/0021-9681(87)90171-8
10.1016/S0920-9964(99)00130-9
ContentType Journal Article
Copyright The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Copyright_xml – notice: The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
DBID AAYXX
CITATION
NPM
7X8
DOI 10.1093/rheumatology/keaa860
DatabaseName CrossRef
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList PubMed
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1462-0332
EndPage 3788
ExternalDocumentID 33331946
10_1093_rheumatology_keaa860
Genre Journal Article
GroupedDBID ---
-E4
.2P
.I3
.XZ
.ZR
08P
0R~
18M
29P
2WC
354
4.4
48X
53G
5RE
5VS
5WA
5WD
70D
AABZA
AACZT
AAJKP
AAMDB
AAMVS
AAOGV
AAPNW
AAPQZ
AAPXW
AARHZ
AAUAY
AAVAP
AAWTL
AAYXX
ABDFA
ABEJV
ABEUO
ABGNP
ABIXL
ABJNI
ABKDP
ABLJU
ABNHQ
ABNKS
ABOCM
ABPTD
ABQLI
ABQNK
ABVGC
ABXVV
ABZBJ
ACGFO
ACGFS
ACPRK
ACUFI
ACUTJ
ACUTO
ACYHN
ADBBV
ADEYI
ADEZT
ADGZP
ADHKW
ADHZD
ADIPN
ADNBA
ADOCK
ADQBN
ADRTK
ADVEK
ADYVW
ADZXQ
AEGPL
AEGXH
AEJOX
AEKSI
AEMDU
AEMQT
AENEX
AENZO
AEPUE
AETBJ
AEWNT
AFFZL
AFIYH
AFOFC
AFXAL
AGINJ
AGKEF
AGORE
AGSYK
AGUTN
AHGBF
AHMBA
AHMMS
AHXPO
AIAGR
AIJHB
AJBYB
AJEEA
AJNCP
AKWXX
ALMA_UNASSIGNED_HOLDINGS
ALUQC
ALXQX
APIBT
APWMN
ATGXG
AXUDD
BAWUL
BAYMD
BCRHZ
BEYMZ
BHONS
BTRTY
BVRKM
C45
CDBKE
CITATION
CS3
CZ4
DAKXR
DIK
DILTD
DU5
D~K
E3Z
EBD
EBS
EE~
EMOBN
ENERS
F5P
F9B
FECEO
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
H13
H5~
HAR
HW0
HZ~
IOX
J21
JXSIZ
KAQDR
KBUDW
KOP
KQ8
KSI
KSN
L7B
M-Z
MHKGH
N9A
NGC
NOMLY
NOYVH
NU-
O9-
OAUYM
OAWHX
OBH
OCZFY
ODMLO
OHH
OJQWA
OJZSN
OPAEJ
OVD
OWPYF
P2P
PAFKI
PEELM
PQQKQ
Q1.
Q5Y
R44
RD5
ROL
ROX
RUSNO
RW1
RXO
SV3
TCURE
TEORI
TJX
TR2
VVN
W8F
WOQ
X7H
YAYTL
YKOAZ
YXANX
ZKX
ZY1
~91
AAUQX
NPM
7X8
ID FETCH-LOGICAL-c307t-cb1fd39bd8f0c84220dffd58718fb9fe77f7cab85d95f561d40acee7aee6370d3
ISSN 1462-0324
1462-0332
IngestDate Fri Jul 11 04:09:28 EDT 2025
Mon Jul 21 06:07:40 EDT 2025
Tue Jul 01 04:04:22 EDT 2025
Thu Apr 24 22:59:04 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 8
Keywords Difficult-to-treat rheumatoid arthritis
contributing factors
risk factors
burden of disease
Language English
License https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model
The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c307t-cb1fd39bd8f0c84220dffd58718fb9fe77f7cab85d95f561d40acee7aee6370d3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-4364-3183
PMID 33331946
PQID 2470899532
PQPubID 23479
PageCount 11
ParticipantIDs proquest_miscellaneous_2470899532
pubmed_primary_33331946
crossref_primary_10_1093_rheumatology_keaa860
crossref_citationtrail_10_1093_rheumatology_keaa860
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20210802
PublicationDateYYYYMMDD 2021-08-02
PublicationDate_xml – month: 08
  year: 2021
  text: 20210802
  day: 02
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Rheumatology (Oxford, England)
PublicationTitleAlternate Rheumatology (Oxford)
PublicationYear 2021
References Westhoff (2021101311241968700_keaa860-B8) 2008; 47
Chang (2021101311241968700_keaa860-B7) 2014; 15
Maxwell (2021101311241968700_keaa860-B9) 2010; 49
Roodenrijs (2021101311241968700_keaa860-B23) 2019; 78
Cella (2021101311241968700_keaa860-B37) 2005; 32
Marra (2021101311241968700_keaa860-B45) 2004; 43
Van Schouwenburg (2021101311241968700_keaa860-B11) 2013; 9
Smolen (2021101311241968700_keaa860-B5) 2020; 79
Richard (2021101311241968700_keaa860-B41) 2019; 78
Jacobi (2021101311241968700_keaa860-B44) 2003; 49
Radner (2021101311241968700_keaa860-B28) 2018; 77
Takanashi (2021101311241968700_keaa860-B39) 2020; 79
de Hair (2021101311241968700_keaa860-B1) 2018; 57
Evers (2021101311241968700_keaa860-B34) 2001; 69
Gossec (2021101311241968700_keaa860-B50) 2019; 86
Harrold (2021101311241968700_keaa860-B13) 2009; 38
Carmona (2021101311241968700_keaa860-B27) 2003; 62
Roodenrijs (2021101311241968700_keaa860-B22)
Donlin (2021101311241968700_keaa860-B52) 2019; 15
Maska (2021101311241968700_keaa860-B35) 2011; 63
Perry (2021101311241968700_keaa860-B48) 2020; 12
Colebatch (2021101311241968700_keaa860-B56) 2013; 72
Buch (2021101311241968700_keaa860-B24) 2019; 78
Naranjo (2021101311241968700_keaa860-B16) 2002; 61
Zigmond (2021101311241968700_keaa860-B32) 1983; 67
Ruiz-Medrano (2021101311241968700_keaa860-B14) 2019; 38
Roodenrijs (2021101311241968700_keaa860-B18)
Roodenrijs (2021101311241968700_keaa860-B49) 2020; 79
Lam (2021101311241968700_keaa860-B47) 2015; 2015
Charlson (2021101311241968700_keaa860-B29) 1987; 40
Batko (2021101311241968700_keaa860-B40) 2019; 38
Englbrecht (2021101311241968700_keaa860-B21) 2013; 42
Thompson (2021101311241968700_keaa860-B31) 2000; 42
Roodenrijs (2021101311241968700_keaa860-B25) 2018; 77
Machin (2021101311241968700_keaa860-B20) 2020; 39
Aletaha (2021101311241968700_keaa860-B26) 2010; 69
Xue (2021101311241968700_keaa860-B12) 2017; 96
Winthrop (2021101311241968700_keaa860-B53) 2020; 79
Imhof (2021101311241968700_keaa860-B10) 2001; 357
Nagy (2021101311241968700_keaa860-B6) 2021; 80
Zhang (2021101311241968700_keaa860-B19) 2020; 23
Kearsley-Fleet (2021101311241968700_keaa860-B3) 2018; 77
Gaujoux-Viala (2021101311241968700_keaa860-B54) 2012; 79
Jacobs (2021101311241968700_keaa860-B55) 2015; 54
Ranzolin (2021101311241968700_keaa860-B17) 2009; 61
Craig (2021101311241968700_keaa860-B38) 2003; 35
Orr (2021101311241968700_keaa860-B51) 2017; 13
(2021101311241968700_keaa860-B43) 2000; 59
Fautrel (2021101311241968700_keaa860-B4) 2012; 14
Buch (2021101311241968700_keaa860-B2) 2018; 77
Broadbent (2021101311241968700_keaa860-B33) 2006; 60
George (2021101311241968700_keaa860-B15) 2016; 18
Verstappen (2021101311241968700_keaa860-B46) 2016; 56
Nikiphorou (2021101311241968700_keaa860-B42) 2019; 58
(2021101311241968700_keaa860-B36) 1990; 16
Wolfe (2021101311241968700_keaa860-B30) 2011; 38
References_xml – volume: 78
  start-page: 1120
  year: 2019
  ident: 2021101311241968700_keaa860-B41
  article-title: SAT0108 Characteristics of multiresistant patients to biological treatments in rheumatoid arthritis, and associated factors: an observational and retrospective study in 385 patients
  publication-title: Ann Rheum Dis
– volume: 357
  start-page: 763
  year: 2001
  ident: 2021101311241968700_keaa860-B10
  article-title: Effect of alcohol consumption on systemic markers of inflammation
  publication-title: Lancet
  doi: 10.1016/S0140-6736(00)04170-2
– volume: 18
  start-page: 1
  year: 2016
  ident: 2021101311241968700_keaa860-B15
  article-title: The obesity epidemic and consequences for rheumatoid arthritis care
  publication-title: Curr Rheumatol Rep
  doi: 10.1007/s11926-015-0550-z
– volume: 77
  start-page: 476
  year: 2018
  ident: 2021101311241968700_keaa860-B28
  article-title: 2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2017-212256
– volume: 38
  start-page: 2473
  year: 2019
  ident: 2021101311241968700_keaa860-B40
  article-title: Comorbidity burden and clinical characteristics of patients with difficult-to-control rheumatoid arthritis
  publication-title: Clin Rheumatol
  doi: 10.1007/s10067-019-04579-1
– volume: 79
  start-page: 685
  year: 2020
  ident: 2021101311241968700_keaa860-B5
  article-title: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2019-216655
– volume: 62
  start-page: 897
  year: 2003
  ident: 2021101311241968700_keaa860-B27
  article-title: Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.62.9.897
– volume: 12
  start-page: 1759720X2090485
  year: 2020
  ident: 2021101311241968700_keaa860-B48
  article-title: The potential value of blood monitoring of biologic drugs used in the treatment of rheumatoid arthritis
  publication-title: Ther Adv Musculoskelet Dis
  doi: 10.1177/1759720X20904850
– volume: 15
  start-page: 22279
  year: 2014
  ident: 2021101311241968700_keaa860-B7
  article-title: Smoking and rheumatoid arthritis
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms151222279
– volume: 60
  start-page: 631
  year: 2006
  ident: 2021101311241968700_keaa860-B33
  article-title: The brief illness perception questionnaire
  publication-title: J Psychosom Res
  doi: 10.1016/j.jpsychores.2005.10.020
– volume: 16
  start-page: 199
  year: 1990
  ident: 2021101311241968700_keaa860-B36
  article-title: EuroQol–a new facility for the measurement of health-related quality of life
  publication-title: Health Policy
  doi: 10.1016/0168-8510(90)90421-9
– volume: 15
  start-page: 327
  year: 2019
  ident: 2021101311241968700_keaa860-B52
  article-title: Insights into rheumatic diseases from next-generation sequencing
  publication-title: Nat Rev Rheumatol
  doi: 10.1038/s41584-019-0217-7
– volume: 42
  start-page: 482
  year: 2013
  ident: 2021101311241968700_keaa860-B21
  article-title: The interaction of physical function and emotional well-being in rheumatoid arthritis – what is the impact on disease activity and coping?
  publication-title: Semin Arthritis Rheum
  doi: 10.1016/j.semarthrit.2012.09.003
– volume: 79
  start-page: 612
  year: 2020
  ident: 2021101311241968700_keaa860-B39
  article-title: FRI0079 characteristics of difficult-to-treat rheumatoid arthritis
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2020-eular.872
– volume: 54
  start-page: 959
  year: 2015
  ident: 2021101311241968700_keaa860-B55
  article-title: Monitoring of rheumatoid arthritis disease activity in individual patients: still a hurdle when implementing the treat-to-target principle in daily clinical practice
  publication-title: Rheumatology
  doi: 10.1093/rheumatology/keu334
– volume: 80
  start-page: 31
  year: 2021
  ident: 2021101311241968700_keaa860-B6
  article-title: EULAR definition of difficult-to-treat rheumatoid arthritis
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2020-217344
– volume: 59
  start-page: 794
  year: 2000
  ident: 2021101311241968700_keaa860-B43
  article-title: Socioeconomic deprivation and rheumatoid disease: what lessons for the health service?
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.59.10.794
– volume: 79
  start-page: 149
  year: 2012
  ident: 2021101311241968700_keaa860-B54
  article-title: Evaluating disease activity in rheumatoid arthritis: which composite index is best? A systematic literature analysis of studies comparing the psychometric properties of the DAS, DAS28, SDAI and CDAI
  publication-title: Joint Bone Spine
  doi: 10.1016/j.jbspin.2011.04.008
– volume: 61
  start-page: 660
  year: 2002
  ident: 2021101311241968700_keaa860-B16
  article-title: Fibromyalgia in patients with rheumatoid arthritis is associated with higher scores of disability
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.61.7.660
– volume: 23
  start-page: 285
  year: 2020
  ident: 2021101311241968700_keaa860-B19
  article-title: Depression has an impact on disease activity and health-related quality of life in rheumatoid arthritis: a systematic review and meta-analysis
  publication-title: Int J Rheum Dis
  doi: 10.1111/1756-185X.13774
– volume: 86
  start-page: 13
  year: 2019
  ident: 2021101311241968700_keaa860-B50
  article-title: Recommendations for the assessment and optimization of adherence to disease-modifying drugs in chronic inflammatory rheumatic diseases: a process based on literature reviews and expert consensus
  publication-title: Joint Bone Spine
  doi: 10.1016/j.jbspin.2018.08.006
– volume: 72
  start-page: 804
  year: 2013
  ident: 2021101311241968700_keaa860-B56
  article-title: EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2012-203158
– volume: 35
  start-page: 1381
  year: 2003
  ident: 2021101311241968700_keaa860-B38
  article-title: International physical activity questionnaire: 12-country reliability and validity
  publication-title: Med Sci Sport Exerc
  doi: 10.1249/01.MSS.0000078924.61453.FB
– volume: 38
  start-page: 2709
  year: 2019
  ident: 2021101311241968700_keaa860-B14
  article-title: The effect of concomitant hand osteoarthritis on pain and disease activity in patients with rheumatoid arthritis
  publication-title: Clin Rheumatol
  doi: 10.1007/s10067-019-04574-6
– volume: 77
  start-page: 966
  year: 2018
  ident: 2021101311241968700_keaa860-B2
  article-title: Defining refractory rheumatoid arthritis
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2017-212862
– volume: 38
  start-page: 1113
  year: 2011
  ident: 2021101311241968700_keaa860-B30
  article-title: Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR preliminary diagnostic criteria for fibromyalgia
  publication-title: J Rheumatol
  doi: 10.3899/jrheum.100594
– volume: 32
  start-page: 811
  year: 2005
  ident: 2021101311241968700_keaa860-B37
  article-title: Validation of the functional assessment of chronic illness therapy fatigue scale relative to other instrumentation in patients with rheumatoid arthritis
  publication-title: J Rheumatol
– volume: 49
  start-page: 2140
  year: 2010
  ident: 2021101311241968700_keaa860-B9
  article-title: Alcohol consumption is inversely associated with risk and severity of rheumatoid arthritis
  publication-title: Rheumatology
  doi: 10.1093/rheumatology/keq202
– volume: 9
  start-page: 164
  year: 2013
  ident: 2021101311241968700_keaa860-B11
  article-title: Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis
  publication-title: Nat Rev Rheumatol
  doi: 10.1038/nrrheum.2013.4
– volume: 13
  start-page: 463
  year: 2017
  ident: 2021101311241968700_keaa860-B51
  article-title: Synovial tissue research: A state-of-the-art review
  publication-title: Nat Rev Rheumatol
  doi: 10.1038/nrrheum.2017.115
– volume: 39
  start-page: 1471
  year: 2020
  ident: 2021101311241968700_keaa860-B20
  article-title: The association between anxiety and disease activity and quality of life in rheumatoid arthritis: a systematic review and meta-analysis
  publication-title: Clin Rheumatol
  doi: 10.1007/s10067-019-04900-y
– ident: 2021101311241968700_keaa860-B22
– volume: 69
  start-page: 1026
  year: 2001
  ident: 2021101311241968700_keaa860-B34
  article-title: Beyond unfavorable thinking: the illness cognition questionnaire for chronic diseases
  publication-title: J Consult Clin Psychol
  doi: 10.1037/0022-006X.69.6.1026
– volume: 69
  start-page: 1580
  year: 2010
  ident: 2021101311241968700_keaa860-B26
  article-title: 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2010.138461
– volume: 57
  start-page: 1135
  year: 2018
  ident: 2021101311241968700_keaa860-B1
  article-title: Difficult-to-treat rheumatoid arthritis: an area of unmet clinical need
  publication-title: Rheumatology
– volume: 78
  start-page: e105
  year: 2019
  ident: 2021101311241968700_keaa860-B23
  article-title: Correspondence to viewpoint ‘Defining refractory rheumatoid arthritis’ by Buch
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2018-214147
– volume: 77
  start-page: 1705
  year: 2018
  ident: 2021101311241968700_keaa860-B25
  article-title: Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2018-213687
– volume: 61
  start-page: 794
  year: 2009
  ident: 2021101311241968700_keaa860-B17
  article-title: Association of concomitant fibromyalgia with worse disease activity score in 28 joints, health assessment questionnaire, and short form 36 scores in patients with rheumatoid arthritis
  publication-title: Arthritis Care Res
  doi: 10.1002/art.24430
– volume: 78
  start-page: e106
  year: 2019
  ident: 2021101311241968700_keaa860-B24
  article-title: Response to ’correspondence to viewpoint ’Defining refractory rheumatoid arthritis’ by Buch’ by Roodenrijs
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2018-214153
– volume: 56
  start-page: 1051
  year: 2016
  ident: 2021101311241968700_keaa860-B46
  article-title: The impact of socio-economic status in rheumatoid arthritis
  publication-title: Rheumatology
– volume: 47
  start-page: 849
  year: 2008
  ident: 2021101311241968700_keaa860-B8
  article-title: Rheumatoid arthritis patients who smoke have a higher need for DMARDs and feel worse, but they do not have more joint damage than non-smokers of the same serological group
  publication-title: Rheumatology
  doi: 10.1093/rheumatology/ken057
– volume: 58
  start-page: 1526
  year: 2019
  ident: 2021101311241968700_keaa860-B42
  article-title: Treatment failure in inflammatory arthritis: time to think about syndemics?
  publication-title: Rheumatology
  doi: 10.1093/rheumatology/kez222
– volume: 43
  start-page: 1390
  year: 2004
  ident: 2021101311241968700_keaa860-B45
  article-title: The impact of low family income on self-reported health outcomes in patients with rheumatoid arthritis within a publicly funded health-care environment
  publication-title: Rheumatology
  doi: 10.1093/rheumatology/keh334
– volume: 67
  start-page: 361
  year: 1983
  ident: 2021101311241968700_keaa860-B32
  article-title: The hospital anxiety and depression scale
  publication-title: Acta Psychiatr Scand
  doi: 10.1111/j.1600-0447.1983.tb09716.x
– volume: 79
  start-page: 88
  year: 2020
  ident: 2021101311241968700_keaa860-B53
  article-title: Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2019-216151
– volume: 96
  start-page: e6983
  year: 2017
  ident: 2021101311241968700_keaa860-B12
  article-title: Bone fracture risk in patients with rheumatoid arthritis
  publication-title: Medicine
  doi: 10.1097/MD.0000000000006983
– volume: 2015
  start-page: 217047
  year: 2015
  ident: 2021101311241968700_keaa860-B47
  article-title: Medication adherence measures: an overview
  publication-title: Biomed Res Int
  doi: 10.1155/2015/217047
– volume: 49
  start-page: 567
  year: 2003
  ident: 2021101311241968700_keaa860-B44
  article-title: Van den Bos GAM. Impact of socioeconomic status on the course of rheumatoid arthritis and on related use of health care services
  publication-title: Arthritis Rheum
  doi: 10.1002/art.11200
– volume: 77
  start-page: 1405
  year: 2018
  ident: 2021101311241968700_keaa860-B3
  article-title: Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2018-213378
– volume: 14
  start-page: R249
  year: 2012
  ident: 2021101311241968700_keaa860-B4
  article-title: Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort
  publication-title: Arthritis Res Ther
  doi: 10.1186/ar4092
– ident: 2021101311241968700_keaa860-B18
  article-title: Diagnostic issues in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis
  publication-title: RMD Open 2021. Accepted for publication.
– volume: 63
  start-page: S4
  year: 2011
  ident: 2021101311241968700_keaa860-B35
  article-title: Measures of functional status and quality of life in rheumatoid arthritis: health Assessment Questionnaire Disability Index (HAQ), Modified Health Assessment Questionnaire (MHAQ), Multidimensional Health Assessment Questionnaire (MDHAQ), Health Assessment
  publication-title: Arthritis Care Res
  doi: 10.1002/acr.20620
– volume: 79
  start-page: 953
  year: 2020
  ident: 2021101311241968700_keaa860-B49
  article-title: SAT0052 Therapeutic strategies in difficult-to-treat rheumatoid arthritis: preliminary results of a systematic literature review informing the 2020 EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis
  publication-title: Ann Rheum Dis
– volume: 38
  start-page: 396
  year: 2009
  ident: 2021101311241968700_keaa860-B13
  article-title: Medication adherence of patients with selected rheumatic conditions: a systematic review of the literature
  publication-title: Semin Arthritis Rheum
  doi: 10.1016/j.semarthrit.2008.01.011
– volume: 40
  start-page: 373
  year: 1987
  ident: 2021101311241968700_keaa860-B29
  article-title: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation
  publication-title: J Chronic Dis
  doi: 10.1016/0021-9681(87)90171-8
– volume: 42
  start-page: 241
  year: 2000
  ident: 2021101311241968700_keaa860-B31
  article-title: Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses
  publication-title: Schizophr Res
  doi: 10.1016/S0920-9964(99)00130-9
SSID ssj0005138
Score 2.622937
Snippet Treatment of difficult-to-treat (D2T) RA patients is generally based on trial-and-error and can be challenging due to a myriad of contributing factors. We...
SourceID proquest
pubmed
crossref
SourceType Aggregation Database
Index Database
Enrichment Source
StartPage 3778
Title Difficult-to-treat rheumatoid arthritis: contributing factors and burden of disease
URI https://www.ncbi.nlm.nih.gov/pubmed/33331946
https://www.proquest.com/docview/2470899532
Volume 60
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Za9wwEBZtCiEvoXe3Fyr0LaixLcmW-1Z6JBS2lDah-2asiyTbrIPXC6W_vqPDR5uGHvtgdn2MWc3HaDSa-Qah50rUKhdFRqzMKWHKKCK4YcSCa80VTxIjXbxj_iE_PGbvF3wx5s_76pJOvlDff1tX8j9ahXOgV1cl-w-aHYTCCfgO-oUjaBiOf6XjNy7g4rgzSNcQnzK-156YDTihzal29EUnnrLIrfp9SrrvbeUyJ2OTHRc0l76OwfmM072anrI7SvM8TY6Y9FufCx-bf0wCCZ-aBgS1p2frYLUBeHvzMQfb1Uk53oqDJhimed2C-7seo7RfYJaODVY-gpl29QFDWMEsXUQmZPXCxLA002BF5qOvSbC2JhhYlmckoSGmecl8B2qrdvLf4OfS1LUITQcmOr0490ql8ElL9gubdpif46Xr6EYGawjX3uJgMcn_SanoaylLuj996X585Q7a7oX87LZcsRbxPsnRTbQbFxP4VUDGLXTNrG6j7XlMl7iDPl8GCB4BggeAvMRTeOAIDwz6xQEeuLE4wuMuOn739uj1IYldNIgC-90RJVOraSm1sIkSLMsSba3msFAWVpbWFIUtVC0F1yW34E1rltTgORW1MTktEk3voa1VszIPENaJgju4ytI8ZzpNJHj3XMNUqwomqClniPaDVKlIMe86nXytQqoDraajXMVRniEyPHURKFb-cP-zfvwrsIVug6temWazrjJWuF1sTrMZuh8UM0jsFfnwyiuP0M4I2cdoq2s35gl4nJ186pHzAw79iO8
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Difficult-to-treat+rheumatoid+arthritis%3A+contributing+factors+and+burden+of+disease&rft.jtitle=Rheumatology+%28Oxford%2C+England%29&rft.au=Roodenrijs%2C+Nadia+M+T&rft.au=van+der+Goes%2C+Marlies+C&rft.au=Welsing%2C+Paco+M+J&rft.au=Tekstra%2C+Janneke&rft.date=2021-08-02&rft.eissn=1462-0332&rft_id=info:doi/10.1093%2Frheumatology%2Fkeaa860&rft_id=info%3Apmid%2F33331946&rft.externalDocID=33331946
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1462-0324&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1462-0324&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1462-0324&client=summon